BrucePaulRandazzoMD

PubMed

• 13 citations
  Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
  Andrew Blauvelt, April W. Armstrong, Richard G. Langley, Kurt Gebauer, Diamant Thaçi, Jerry Bagel, Lyn Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hs...> ;The Journal of Dermatological Treatment. 2021 Aug 4
• 3 citations
  Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
  Luis Puig, Jashin J. Wu, Melinda Gooderham, Yin You, Yaung-Kaung Shen, Bruce Randazzo, Francisco A. Kerdel> ;The Journal of Dermatological Treatment. 2021 Jul 4
• 2 citations
  Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
  Wangda Zhou, Chuanpu Hu, Yaowei Zhu, Bruce Randazzo, Michael Song, Amarnath Sharma, Zhenhua Xu, Honghui Zhou> ;Clinical Pharmacology and Therapeutics. 2021 Jan 1
• 60 citations
  Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
  Kristian Reich, Christopher E.M. Griffiths, Kenneth B. Gordon, Kim A. Papp, Michael Song, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Chenglong Han, Alexa B. Kimball, Ap...> ;Journal of the American Academy of Dermatology. 2020 Apr 1
• 41 citations
  Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker...
  Sandra Philipp, Alan Menter, Arjen Nikkels, K. Barber, Ian Landells, Lawrence F. Eichenfield, Michael Song, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Yaowei Zhu, S. DePri...> ;The British Journal of Dermatology. 2020 Mar 16
• 196 citations
  Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
  Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt> ;Lancet. 2019 Sep 7
• 49 citations
  Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
  Kristian Reich, Kim Papp, April W. Armstrong, Y. Wasfi, Shu Li, Yaung-Kaung Shen, Bruce Randazzo, Michael Song, Alexa B. Kimball> ;The British Journal of Dermatology. 2019 May 1
• 17 citations
  Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.
  Yaowei Zhu, Joseph C. Marini, Michael Song, Bruce Randazzo, Yaung-Kaung Shen, Shu Li, Honghui Zhou> ;The Journal of Investigative Dermatology. 2019 Aug 1
• 21 citations
  Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
  Kim Papp, Andrew Blauvelt, Alexa B. Kimball, Chenglong Han, Bruce Randazzo, Y. Wasfi, Yaung-Kaung Shen, Shu Li, Christopher E.M. Griffiths> ;Journal of the European Academy of Dermatology and Venereology. 2018 Sep 1
• 8 citations
  Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multi...
  Ellen H. Frankel, Michael Song, Shu Li, Jingzhi Jiang, Robin L Thurmond, Bruce Randazzo> ;Journal of Drugs in Dermatology. 2018 Aug 1
• 35 citations
  Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
  Christopher E.M. Griffiths, Kim A. Papp, Alexa B. Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt> ;Journal of Drugs in Dermatology. 2018 Aug 1
• 69 citations
  Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
  Peter Foley, Kenneth B. Gordon, Christopher E.M. Griffiths, Y. Wasfi, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt> ;JAMA Dermatology. 2018 Jun 1
• 33 citations
  Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
  Zhenling Yao, Chuanpu Hu, Yaowei Zhu, Zhenhua Xu, Bruce Randazzo, Y. Wasfi, Yang Chen, Amarnath Sharma, Honghui Zhou> ;Journal of Clinical Pharmacology. 2018 May 1
• 14 citations
  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
  Chuanpu Hu, Zhenling Yao, Yang Chen, Bruce Randazzo, Liping Zhang, Zhenhua Xu, Amarnath Sharma, Honghui Zhou> ;Journal of Pharmacokinetics and Pharmacodynamics. 2018 Mar 16
• 49 citations
  Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
  Kenneth B. Gordon, Andrew Blauvelt, Peter Foley, Michael Song, Y. Wasfi, Bruce Randazzo, Yaung-Kaung Shen, Yin You, Christopher E.M. Griffiths> ;The British Journal of Dermatology. 2018 Jan 1
• 217 citations
  Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGAT...
  Richard G. Langley, Tsen-Fang Tsai, Susan Flavin, Michael Song, Bruce Randazzo, Y. Wasfi, Jingzhi Jiang, Shu Li, Lluís Puig> ;The British Journal of Dermatology. 2018 Jan 1
• 18 citations
  Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoria...
  Chuanpu Hu, Bruce Randazzo, Amarnath Sharma, Honghui Zhou> ;Journal of Pharmacokinetics and Pharmacodynamics. 2017 Jun 20
• 107 citations
  Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, ...
  Arthur Kavanaugh, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Yin You, Shu Li, Michael Song, Bruce Randazzo, Proton Rahman, Iain B. McInnes> ;Annals of the Rheumatic Diseases. 2016 Apr 20
• 529 citations
  Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to sever...
  Andrew Blauvelt, Kim A. Papp, Christopher E.M. Griffiths, Bruce Randazzo, Y. Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B. Kimball> ;Journal of the American Academy of Dermatology. 2017 Mar 1
• 417 citations
  Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis...
  Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Y. Wasfi, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Kenneth B. Gordon> ;Journal of the American Academy of Dermatology. 2017 Mar 1
• 46 citations
  HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program
  Katherine Li, Conway C. Huang, Bruce Randazzo, Shu Li, Philippe Szapary, Mark Curran, Kim Campbell, Carrie Brodmerkel> ;The Journal of Investigative Dermatology. 2016 Dec 1
• 153 citations
  Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
  Ian Landells, Colleen Marano, Ming Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Alain Taieb, Sandra Philipp, Phi...> ;Journal of the American Academy of Dermatology. 2015 Oct 1
• 231 citations
  A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
  Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C. Prinz, Y. Wasfi, Shu Li, Yaung Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich> ;The New England Journal of Medicine. 2015 Jul 8
• 13 citations
  Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis.
  Edward Michna, Arnold J. Weil, Marc Duerden, Seth Schulman, Wenjin Wang, Evan Tzanis, Haiying Zhang, Dahong Yu, Amy Manley, Bruce Randazzo> ;Pain Medicine. 2011 Aug 1
• 105 citations
  Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Patients With Chronic, Nonmalignant Pain: A Randomized Controlled Study
  Edward Michna, E. Richard Blonsky, Seth Schulman, Evan Tzanis, Amy Manley, Haiying Zhang, Shrividya Iyer, Bruce Randazzo> ;The Journal of Pain. 2011 May 1
• Join now to see all

Journal Articles

• Efficacy of Guselkumab Compared with Adalimumab and Placebo for Psoriasis in Specific Body Regions  
  Bruce Randazzo, Andrew Blauvelt, JAMA